Mezigdomide (MEZI) Combination Therapy for Relapsed/Refractory Multiple Myeloma – Insights from CC-92480-MM-002 Trial
Dr. Paul G. Richardson reports on the use of various mezigdomide combinations in the treatment of relapsed/refractory multiple myeloma.
Abstract Title:
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial Presented at ASH 2023
What is the purpose of this trial?
The purpose of the CC-92480-MM-002 trial is to investigate a new treatment called mezigdomide (MEZI) for people with relapsed/refractory multiple myeloma (RRMM). MEZI is a unique oral medication that modulates a protein called cereblon to enhance its effectiveness against cancer cells. In earlier studies, MEZI demonstrated promising effects when combined with other anti-myeloma drugs like dexamethasone (DEX), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs).
This trial, conducted in phases I and II, is evaluating the safety and effectiveness of MEZI in different combinations with other drugs for RRMM. The combinations being studied are MEZI with daratumumab (DARA) and dexamethasone (DEX) (referred to as MeziDd); and MEZI with elotuzumab (ELO) and DEX (referred to as MeziEd). The goal is to understand how well these combinations work in patients with RRMM and to assess their safety. The researchers will report preliminary findings on the effectiveness and safety of these treatment combinations over various dosing schedules.
In this video:
Pau G. Richardson, MD, (Dana-Farber Cancer Institute — Boston, MA) reports on the use of various mezigdomide combinations in the treatment of relapsed/refractory multiple myeloma. The primary objective of this trial was “to determine the recommended dose and regimen and to assess safety and preliminary efficacy as overall response rate.”
Conclusion:
From the abstract: “MeziDd showed promising efficacy and a manageable safety profile in patients with RRMM and 2 to 4 prior lines of therapy, as did MeziEd in patients with prior anti-CD38 mAb therapy. The immune activity of MEZI was consistent with previous preclinical reports. Improved safety and efficacy may be achieved by schedule and dose adjustments. These results support further evaluation of MEZI plus anti-myeloma mAbs in phase I/II and phase III studies.”
Trial Information: Abstract #1013
Doctor Bio:
Paul G. Richardson, MD, received certifications in Internal Medicine, Hematology, and Medical Oncology. Joining the Jerome Lipper Myeloma Center in 1999, Dr. Richardson eventually became the Clinical Director in 2001. His pivotal contributions include leading the development of groundbreaking drugs such as Velcade® (bortezomib), Revlimid® (lenalidomide), and Pomalyst® (pomalidomide) for the treatment of multiple myeloma. Over the years, he has focused on next-generation novel drugs, exploring compounds like panobinostat and second-generation proteasome inhibitors, including Ninlaro® (ixazomib).
Dr. Richardson's recent endeavors have centered on pioneering monoclonal antibodies like Empliciti™ (elotuzumab) and Darzalex® (daratumumab), as well as advancing antibody drug conjugates, including Blenrep® (belantamab mafodotin), and other innovative immunotherapeutic strategies. Notable contributions include his leadership in the development of melflufen, a targeted cytotoxic; and the groundbreaking small molecule inhibitor Xpovio® (selinexor), targeting the key protein XPO-1. He is also at the forefront of research on cereblon E3 ligase modulators (CELMoDs) for relapsed and refractory myeloma.
With an extensive publication record comprising over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals, Dr. Richardson has established himself as a leading figure in the field. His leadership roles in organizations such as the Multiple Myeloma Research Consortium (MMRC) and the Alliance Myeloma Committee underscore his commitment to collaborative research. Among numerous awards, he was also the 2017 recipient of the IMF’s Robert A. Kyle Lifetime Achievement Award.
